High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma

• Published in: Leukemia & lymphoma Vol. 51; no. 3; pp. 406 - 414
• Main Authors: Lossos, Izidore S., Hosein, Peter J., Morgensztern, Daniel, Coleman, Francine, Escalón, Maricer P., Byrne, Gerald E., Rosenblatt, Joseph D., Walker, Gail R.
• Format: Journal Article
• Language: English
• Published: United States Informa UK Ltd 01.03.2010; Taylor & Francis
• Subjects: Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy; Cyclophosphamide - administration & dosage; Cytarabine - administration & dosage; Cytarabine - therapeutic use; Disease-Free Survival; Doxorubicin - administration & dosage; Drug Administration Schedule; Etoposide - administration & dosage; Etoposide - therapeutic use; Female; Humans; Ifosfamide - administration & dosage; Ifosfamide - therapeutic use; Lymphoma, Mantle-Cell - drug therapy; Male; mantle cell lymphoma; Methotrexate - administration & dosage; Methotrexate - therapeutic use; Middle Aged; Remission Induction; Rituximab; thalidomide; Thalidomide - administration & dosage; Treatment Outcome; Vincristine - administration & dosage
• ISSN: 1042-8194; 1029-2403
• DOI: 10.3109/10428190903518345

Novel therapeutic approaches are needed in mantle cell lymphoma (MCL). We conducted a phase II study in MCL testing an intensive regimen, R-MACLO-IVAM-T, a modification of the NCI 89-C-41 protocol. Newly diagnosed patients were treated with rituximab, methotrexate, doxorubicin, cyclophosphamide, and vincristine (cycle 1) followed by rituximab, ifosfamide (and mesna), etoposide, and cytarabine (cycle 2). These two cycles were repeated once, and patients achieving complete response (CR) received maintenance thalidomide. Among the 22 patients enrolled, 21 completed two or more cycles and achieved a CR. Three patients relapsed, while 17 are alive and relapse-free after a median follow-up of 37 months (range 19-65 months). Two patients died: one from sepsis during cycle 1 and another at 38 months while in remission from MCL. The progression-free survival at 3 years was 78% (95% CI: 51-91%). These results compare favorably with previously reported outcomes suggesting that durable remissions can be achieved without myeloablative therapy.